Literature DB >> 10391654

Perceived health over 3 years after percutaneous coronary balloon angioplasty.

G Permanyer-Miralda1, J Alonso, C Brotons, P Cascant, A Ribera, I Moral, B Romero, E Domingo, J M Antó, J Soler-Soler.   

Abstract

The magnitude of the benefit of percutaneous transluminal coronary angioplasty (PTCA) in terms of quality of life depending on baseline and outcome clinical variables is not sufficiently understood because of the restrictive inclusion criteria of randomized clinical trials. The present study was designed to assess perceived health outcome at 3 years and its association with clinical variables after successful elective PTCA in a tertiary hospital throughout a prospective cohort study. Questionnaires were administered on the day before the procedure and 1 month and 3.4 years later (as mean follow-up) to 106 patients recruited during a 15-month period. Mean perceived health scores improved significantly for the population as a whole 1 month after PTCA, and improvement was maintained at the end of follow-up. The magnitude of the effect was different depending on clinical subgroups: (a) It was greatest in patients free from angina, myocardial infarction, or new revascularization procedures at the end of follow-up; (b) It was moderately reduced in patients with comorbidity; (c) Patients who reported to have dyspnea or angina at rest after the latest revascularization procedure did not improve, with poor final perceived health scores. Elective PTCA is associated with a significant improvement in perceived health, which varies depending on the clinical outcome. Comorbidity and initial perceived health influence outcome but do not preclude improvement.

Entities:  

Mesh:

Year:  1999        PMID: 10391654     DOI: 10.1016/s0895-4356(99)00045-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Expected treatment benefits of percutaneous transluminal coronary angioplasty: the patient's perspective.

Authors:  O Ozkan; J Odabasi; U Ozcan
Journal:  Int J Cardiovasc Imaging       Date:  2008-02-05       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.